Respiratory Distress Syndrome clinical trials at UCSF

2 research studies open to eligible people

Respiratory distress syndrome makes it hard for the lungs to get oxygen into the blood. UCSF is exploring how ECMO impacts children's brain health after sudden lung failure. UCSF is also testing a stem cell treatment to see if it can safely improve lung health in affected patients.

Showing trials for

  • Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

    open to eligible people ages 18-75

    To evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EVs), ExoFlo, versus placebo for the treatment of hospitalized patients with moderate-to-severe Acute Respiratory Distress Syndrome (ARDS).

    San Francisco, California and other locations

  • ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)

    open to eligible people ages up to 20 years

    ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatric intensive care unit. The second objective is to compare short and long-term patient outcomes in two groups of children: one group managed with a mechanical ventilation protocol that reserves the use of extracorporeal membrane oxygenation (ECMO) until protocol failure to another group supported on ECMO per usual care.

    Oakland, California and other locations

Last updated: